Ontology highlight
ABSTRACT: Background
Although several prognostic genomic predictors have been identified from independent studies, it remains unclear whether these predictors are actually concordant with respect to their predictions for individual patients and which predictor performs best. We compared five prognostic genomic predictors, the V7RHS, the ColoGuideEx, the Meta163, the OncoDX, and the MDA114, in terms of predicting disease-free survival in two independent cohorts of patients with colorectal cancer.Study design
Using original classification algorithms, we tested the predictions of five genomic predictors for disease-free survival in two cohorts of patients with colorectal cancer (n?=?229 and n?=?168) and evaluated concordance of predictors in predicting outcomes for individual patients.Results
We found that only two predictors, OncoDX and MDA114, demonstrated robust performance in identifying patients with poor prognosis in 2 independent cohorts. These two predictors also had modest but significant concordance of predicted outcome (r>0.3, P<0.001 in both cohorts).Conclusions
Further validation of developed genomic predictors is necessary. Despite the limited number of genes shared by OncoDX and MDA114, individual-patient outcomes predicted by these two predictors were significantly concordant.
SUBMITTER: Park YY
PROVIDER: S-EPMC3634034 | biostudies-literature | 2013
REPOSITORIES: biostudies-literature
Park Yun-Yong YY Lee Sung Sook SS Lim Jae Yun JY Kim Sang Cheol SC Kim Sang Bae SB Sohn Bo Hwa BH Chu In-Sun IS Oh Sang Cheul SC Park Eun Sung ES Jeong Woojin W Kim Sung Soo SS Kopetz Scott S Lee Ju-Seog JS
PloS one 20130423 4
<h4>Background</h4>Although several prognostic genomic predictors have been identified from independent studies, it remains unclear whether these predictors are actually concordant with respect to their predictions for individual patients and which predictor performs best. We compared five prognostic genomic predictors, the V7RHS, the ColoGuideEx, the Meta163, the OncoDX, and the MDA114, in terms of predicting disease-free survival in two independent cohorts of patients with colorectal cancer.<h ...[more]